Zadaxin: The Brand Name Thymosin Alpha-1
Thymosin Alpha-1
35+ Countries
Zadaxin (thymalfasin) is approved in over 35 countries for hepatitis B, hepatitis C, and immunodeficiency, but has never received FDA approval in the United States.
Dinetz & Lee, Alternative Therapies, 2024
Dinetz & Lee, Alternative Therapies, 2024
View as imageZadaxin is the brand name for thymalfasin, a synthetic 28-amino-acid peptide identical in sequence to the naturally occurring thymosin alpha-1 (Ta1) produced by the thymus gland. It is one of the most widely prescribed peptide immunomodulators in the world, approved in over 35 countries for treating chronic hepatitis B, hepatitis C, and various immunodeficiency states. It has never been approved by the FDA. This split between global use and American absence defines Zadaxin's unusual position in peptide therapeutics. For a comprehensive overview of the peptide itself, see our pillar article on Thymosin Alpha-1: The Immune-Modulating Peptide.
Key Takeaways
- Zadaxin (thymalfasin) is a synthetic 28-amino-acid peptide approved in over 35 countries, primarily for chronic hepatitis B and immunodeficiency
- SciClone Pharmaceuticals launched Zadaxin in the 1990s, generating $39.5 million in Q1 2017 revenue alone before the company was acquired for $605 million
- A comprehensive 2024 review of human clinical trials found Zadaxin was safe and well tolerated across all studied indications (Dinetz & Lee)
- The TESTS trial (Wu et al., BMJ, 2025), a multicenter Phase 3 trial with 1,106 sepsis patients, is the largest randomized controlled trial of thymosin alpha-1 to date
- Zadaxin is not FDA-approved in the United States, where thymosin alpha-1 is available only through compounding pharmacies under 503B regulations
- China accounts for the majority of global Zadaxin sales, where it is used as both a hepatitis treatment and an immune support therapy in oncology
From Thymus Extract to Synthetic Peptide
Thymosin alpha-1 was first isolated by Allan Goldstein's lab at George Washington University in 1977, purified from bovine thymus tissue. The thymus gland, which sits behind the sternum and is most active during childhood, produces peptides that guide T-cell maturation and immune system development. Ta1 was identified as the primary immunologically active component of a crude thymus extract called thymosin fraction 5.
The peptide is small (3,108 Da), acetylated at its N-terminus, and has no disulfide bonds. Its simplicity made it an ideal candidate for chemical synthesis. By the 1980s, fully synthetic thymalfasin was produced by solid-phase peptide synthesis, eliminating the need for animal-derived material and enabling standardized pharmaceutical production.
SciClone Pharmaceuticals (later SciClone Pharma) licensed the rights and developed the synthetic peptide under the brand name Zadaxin. The standard formulation is a lyophilized powder for subcutaneous injection, typically dosed at 1.6 mg twice weekly.
Global Approval and Market Presence
Zadaxin's approval geography reflects the burden of disease. Hepatitis B is endemic in East and Southeast Asia, where chronic infection affects 5-10% of the population. Zadaxin found its largest market in countries where the clinical need was greatest.
China became Zadaxin's primary market, accounting for the majority of global sales. It was approved for chronic hepatitis B (both as monotherapy and combined with interferon-alpha) and became widely used in oncology as an immune support therapy during chemotherapy.
Other Asia-Pacific markets: Approvals in the Philippines, Singapore, India (2001), and other countries in the region followed.
Latin America: Argentina granted approval for both HBV and HCV indications. Peru also approved the drug.
Europe and Middle East: Several countries granted approval, though European Medicines Agency (EMA) centralized approval was never sought.
United States: Zadaxin has never been submitted for or granted FDA approval. The company reportedly considered the cost and timeline of FDA registration trials prohibitive given the available market opportunity elsewhere. In the US, thymosin alpha-1 is available through compounding pharmacies under Section 503B of the Federal Food, Drug, and Cosmetic Act, where it is prescribed off-label by physicians.
By Q1 2017, Zadaxin revenues reached $39.5 million, a 17% increase from the same quarter in 2016. That same year, SciClone Pharmaceuticals was acquired for $605 million by a consortium including GL Capital Management, Bank of China Group Investment, CDH Investments, and Ascendent Capital Partners.
Clinical Evidence: What the Trials Show
Hepatitis B
The foundational indication. Multiple randomized controlled trials demonstrated that Zadaxin, both as monotherapy and combined with interferon-alpha, increased sustained virological response rates (HBeAg seroconversion and HBV DNA suppression) in chronic hepatitis B patients. The combination of thymalfasin plus interferon-alpha consistently outperformed interferon-alpha alone. For the full trial evidence, see Thymosin Alpha-1 for Hepatitis B.
The mechanism is immunomodulatory rather than directly antiviral. Thymosin alpha-1 enhances dendritic cell maturation, promotes Th1-type immune responses, and increases the activity of natural killer cells and cytotoxic T-lymphocytes against virus-infected hepatocytes. It shifts the immune response toward viral clearance rather than the immune tolerance that characterizes chronic HBV infection. For more on this mechanism, see How Thymosin Alpha-1 Matures T-Cells.
Sepsis: The TESTS Trial
Wu et al. (2025) published the TESTS trial in the BMJ, the largest randomized controlled trial of thymosin alpha-1 in any indication. This multicenter, double-blind, Phase 3 trial enrolled 1,106 patients with sepsis across multiple Chinese hospitals.[1]
The rationale for testing an immunomodulator in sepsis is that many sepsis deaths occur not during the initial hyperinflammatory phase, but during the subsequent immunosuppressed state. Patients who survive the initial infection often develop profound immune paralysis, leaving them vulnerable to secondary infections. Thymosin alpha-1's ability to restore T-cell function and enhance innate immunity makes it a logical candidate for this immunoparalysis phase. For broader context, see Thymosin Alpha-1 for Sepsis.
Pei et al. (2018) had earlier reviewed the preclinical and clinical rationale for thymosin alpha-1 in sepsis, documenting evidence that it could improve lymphocyte counts, increase HLA-DR expression on monocytes, and reduce secondary infection rates in critically ill patients.[2]
Cancer: Immunotherapy Adjunct
Thymosin alpha-1 has been studied as an adjunct to cancer immunotherapy and chemotherapy. Mao (2023) reviewed the landscape and argued that the immuno-oncology era presents new opportunities for thymosin alpha-1 as a combination agent, particularly with checkpoint inhibitors.[3]
Yao et al. (2025) published a retrospective study showing that thymosin alpha-1 combined with lenvatinib plus sintilimab (a PD-1 inhibitor) in unresectable hepatocellular carcinoma produced objective response rates and progression-free survival data that warrant further investigation in controlled trials.[4]
Solmonese et al. (2025) characterized the immunomodulatory activity of thymosin alpha-1 on tumor cell lines and distinct immune cell subsets, finding that it enhanced antigen presentation and T-cell activation in vitro across multiple cancer types.[5]
For the full cancer research landscape, see Thymosin Alpha-1 in Cancer.
Respiratory Infections and COVID-19
The COVID-19 pandemic renewed interest in thymosin alpha-1 as an immune modulator for severe respiratory infections. Bellet et al. (2023) reassessed the role of thymosin alpha-1 in lung infections beyond COVID, reviewing evidence that it modulates inflammatory pathways, enhances pathogen clearance, and may reduce the risk of secondary infections in immunocompromised patients.[6]
Safety Profile
Dinetz and Lee (2024) published a comprehensive review of thymosin alpha-1 safety across all human clinical trials. The review concluded that Zadaxin was safe and well tolerated across all studied indications, with injection site reactions being the most common adverse event. No dose-limiting toxicities were identified, and no serious adverse events were attributed to the drug.[7]
Aging and Thymosin Alpha-1
Simonova et al. (2025) reviewed the relationship between aging, thymic involution, and thymosin alpha-1 decline. As the thymus atrophies with age (beginning in puberty and accelerating after age 40), endogenous thymosin alpha-1 production falls. This decline correlates with the age-related weakening of adaptive immunity, reduced vaccine responsiveness, and increased susceptibility to infections and cancer in older adults.[8]
The review proposed that exogenous thymosin alpha-1 supplementation could partially compensate for thymic involution, though the evidence base for this application in otherwise healthy older adults remains limited to small studies. The aging connection also explains one of Zadaxin's off-label use patterns: physicians in countries where it is available prescribe it to elderly patients with recurrent infections or poor immune function as a general immune support measure. Thymosin Alpha-1 as a Vaccine Adjuvant is a related application, with studies showing it can improve vaccine response rates in immunocompromised elderly populations.
Zadaxin vs. Compounded Thymosin Alpha-1
In the United States, thymosin alpha-1 is available through Section 503B compounding pharmacies. The distinction between pharmaceutical-grade Zadaxin and compounded thymosin alpha-1 is worth understanding.
Manufacturing standards. Zadaxin is produced under current Good Manufacturing Practice (cGMP) conditions with batch-to-batch consistency testing, stability studies, and regulatory oversight from approving national agencies. Compounded thymosin alpha-1 is produced in smaller batches by 503B outsourcing facilities under FDA oversight, but with less stringent requirements than approved drugs. Purity, potency, and sterility standards exist but are not equivalent to those for approved biologics.
Dosing and formulation. Zadaxin is standardized at 1.6 mg per vial with specific reconstitution instructions. Compounded versions may vary in concentration, excipients, and presentation. Some compounding pharmacies provide pre-filled syringes; others supply lyophilized powder.
Quality control. The peptide itself is the same 28-amino-acid sequence regardless of source. The concern with compounded versions is not the molecular identity but the manufacturing process. Impurities from incomplete synthesis, degradation products from improper storage, and sterility failures are the primary risks. These risks are manageable with reputable 503B facilities but are not zero.
Cost. Zadaxin in markets where it is approved is priced as a branded pharmaceutical. Compounded thymosin alpha-1 in the US is typically less expensive per dose but is not covered by insurance.
Why Zadaxin Was Never FDA-Approved
The absence of FDA approval does not reflect negative data. It reflects a business decision. FDA registration for a new biologic requires large, expensive Phase 3 trials conducted to FDA standards, typically costing hundreds of millions of dollars. SciClone calculated that the revenue from the US hepatitis B market (which is smaller than Asia's, and where effective antiviral drugs like tenofovir and entecavir were already available) would not justify the investment.
Garaci et al. (2024) argued that thymosin alpha-1's drug discovery trajectory, driven by phenotypic observations rather than target-based screening, made it harder to fit into the FDA's preferred framework of well-characterized molecular targets and mechanisms.[9] The peptide's pleiotropic immunomodulatory effects, touching dendritic cells, T-cells, NK cells, and toll-like receptor signaling, made it difficult to design trials around a single primary endpoint.
The result is a paradox: one of the most widely used peptide immunomodulators in the world is unavailable as an approved drug in the world's largest pharmaceutical market.
The Future of Thymosin Alpha-1 Beyond Zadaxin
Several developments are reshaping the thymosin alpha-1 landscape.
Immuno-oncology combinations. The rise of checkpoint inhibitors (anti-PD-1, anti-PD-L1) has created new interest in combining thymosin alpha-1 with these agents. The rationale is additive: checkpoint inhibitors remove the brakes on T-cell activity, while thymosin alpha-1 promotes T-cell maturation and activation. Early data from the HCC combination study (Yao et al., 2025) suggests this approach warrants controlled investigation.
Sepsis and critical care. The TESTS trial represents a new level of evidence for thymosin alpha-1 in sepsis. Regardless of the specific trial outcome, the fact that a multicenter, double-blind, Phase 3 trial was completed and published in the BMJ signals that the evidence base has matured beyond the small, single-center studies that characterized earlier research.
Aging and immune restoration. As the population ages globally and thymic involution becomes a recognized driver of immune decline, the concept of thymosin alpha-1 supplementation for age-related immunosenescence is gaining traction. The challenge is designing trials with meaningful clinical endpoints (infection rates, vaccine responsiveness, mortality) rather than surrogate markers (lymphocyte counts, cytokine levels).
Generic competition. As patents expire and biosimilar pathways mature, multiple manufacturers now produce thymalfasin for markets outside the US and Europe. This competition is reducing prices and expanding access, particularly in middle-income countries where hepatitis B burden is high but healthcare budgets are constrained.
Regulatory evolution. The FDA's increasing comfort with peptide therapeutics (evidenced by approvals of semaglutide, tirzepatide, and other peptide drugs) may eventually create a more favorable environment for a thymosin alpha-1 approval application, though no such application appears imminent.
The Bottom Line
Zadaxin (thymalfasin) is a synthetic copy of thymosin alpha-1 approved in over 35 countries for hepatitis B, immunodeficiency, and related conditions. Its clinical evidence spans hepatitis, sepsis, cancer immunotherapy, and respiratory infections. The TESTS trial (BMJ, 2025) with 1,106 sepsis patients represents the strongest controlled evidence to date. Despite decades of use and a strong safety record, Zadaxin has never been FDA-approved, a consequence of commercial calculation rather than scientific concern. In the US, thymosin alpha-1 remains available only through compounding pharmacies.